HRMY - Cash Flow Statement - Harmony Biosciences Holdings, Inc.

Millions

	Dec-2024	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018
OPERATING CASH FLOW
Net Income	145.5	128.9	181.5	34.6	(36.9)	(152.0)	(39.9)
Depreciation & Amortization	24.1	24.4	23.4	18.8	10.2	3.2	0.2
Deferred Income Tax	(29.3)	(13.4)	(85.9)	26.1	25.7	0	0
Stock Based Compensation	42.6	31.7	26.2	15.7	4.7	9.9	1.1
Other Operating Activities	36.9	12.9	3.5	2.7	4.9	55.1	2.1
Change in Working Capital	0	35.0	(4.1)	0.6	(11.6)	8.3	(0.2)
Cash From Operations	219.8	219.4	144.5	98.6	(3.0)	(75.4)	(38.8)
INVESTING CASH FLOW
Capital Expenditures	(1.2)	(0.3)	(40.2)	(100.3)	(2.0)	(127.1)	(1.3)
Other Items	(66.3)	(46.1)	(101.7)	0	0	0	0
Cash From Investing Activities	(67.5)	(46.4)	(141.8)	(100.3)	(2.0)	(127.1)	(1.3)
FINANCING CASH FLOW
Common Stock Repurchased	0	(100.0)	0	0	(0.2)	(1.1)	(3.2)
Total Debt Repaid	(15.0)	(1.2)	(2.0)	(0.5)	79.4	100.0	0
Dividends Paid	0	0	0	0	0	0	0
Other Financing Activities	4.0	(4.3)	8.8	(22.1)	(17.7)	93.8	24.8
Cash From Financing Activities	(11.0)	(105.6)	6.8	7.4	209.2	143.8	21.6
CHANGE IN CASH
Net Change In Cash	141.3	67.4	9.5	5.7	204.2	(58.8)	(18.5)
FREE CASH FLOW
Free Cash Flow	218.7	219.1	104.3	(1.7)	(5.0)	(202.6)	(40.1)

Free